Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: early-phase trial registry
2 of 6 indexed Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: 6 US clinical trials tracked, 2 recruiting.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 3 of these trials.
Enrollment posture brief
Registry condition anti-neutrophil-cytoplasmic-antibody-associated-vasculitis
OPEN 2 | RECR 33% | LATE 1 | EARLY 5 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis research.
Amgen accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials plan to enrol fewer than 100 people.
Median target enrolment is 72 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Amgen
NCT06072482
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Nkarta
NCT06733935
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Alpine Immune Sciences
NCT05732402
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
Sana Biotechnology
NCT06294236
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
Amgen
NCT06004947
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
Amgen
NCT05988021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis condition card totals 6 registered trials; most-linked intervention CCX168; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.